<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965129</url>
  </required_header>
  <id_info>
    <org_study_id>40240420.2.0000.5533</org_study_id>
    <nct_id>NCT04965129</nct_id>
  </id_info>
  <brief_title>Supplementation of n-3 PUFA in the Modulation of Lean Mass in Patients With Lung Cancer Receiving a High-protein Diet</brief_title>
  <official_title>Effect of Supplementation of n-3 Polyunsaturated Fatty Acids and a High Protein Diet on Modulation of Muscle Mass and Intestinal Microbiota in Patients With Lung Cancer Undergoing Treatment With Immunotherapeutic Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institutos Madrileño de Estudios Avanzados IMDEA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncoclínicas</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to test the hypothesis that patients with lung cancer undergoing&#xD;
      immunotherapy receiving a high protein diet and supplemented with fish oil will improve&#xD;
      muscle mass, therapeutic response and modulate the intestinal microbiota within a 4 month&#xD;
      period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer (PC) is the most prevalent tumor. The loss of muscle mass, myosteatosis and&#xD;
      changes in body composition have been associated with inflammation in cancer and PUFA n-3&#xD;
      have been shown to be an important modulator of the inflammatory response and epigenetic&#xD;
      mechanisms. Additionally, the intestinal microbiome has received prominence with the use of&#xD;
      immunotherapy, as it is demonstrating that resistance to this therapy can be attributed to&#xD;
      the abnormal composition of the intestinal microbiome. Aims: The purpose of this study is to&#xD;
      assess the effects of fish oil supplementation in the modulation of lean mass and intestinal&#xD;
      microbiome in patients with lung cancer undergoing immunotherapy receiving a high-protein&#xD;
      diet. Methods: Fifty patients will be randomly allocated either to treatment with fish oil or&#xD;
      to placebo for 4 months. The following assessments will be made: lean mass, myosteatosis,&#xD;
      sarcopenia, adipose compartment, inflammation, micro RNA 133, food consumption, membrane&#xD;
      phospholipid composition, composition of the intestinal microbiota, toxicity, response to&#xD;
      antineoplastic treatment and survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change/maintenance in overall skeletal muscle density.</measure>
    <time_frame>16 weeks</time_frame>
    <description>To assess the change/maintenance in muscle density from baseline to week 16 using computed tomography (CT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle mass</measure>
    <time_frame>16 weeks</time_frame>
    <description>CT-derived changes in muscle mass ocurring from baseline to week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell omega-3 fatty acid concentrations (eicosapentaenoic [EPA] and docosahexaenoic acid [DHA]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assessed by gas chromatography (GC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strenght</measure>
    <time_frame>16 weeks</time_frame>
    <description>Hand grip strength test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fecal microbiome composition</measure>
    <time_frame>16 weeks</time_frame>
    <description>alpha- and beta-diversity of 16S bacterial rDNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in levels of miRNA 133</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measure the plasma levels of miRNA 133 from baseline to week 16 by real-time PCR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator: Placebo All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given four tablet/day for four mounths.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Fish oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be given fish oil with a dose of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug: Placebo olive oil pill manufactured to mimic fish oil. Other Names: • Placebo</description>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fish oil</intervention_name>
    <description>All subjects will be given fish oil with a dose of of 2.100 mg of EPA and 924 mg of DHA, in four tablet twice daily for four mounths.</description>
    <arm_group_label>Experimental: Fish oil</arm_group_label>
    <other_name>Vital Fish</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of non-small cell lung cancer, both sexes, ECOG performance status (0-1),&#xD;
             treatment virgin, eligible for immunotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  supplementation of PUFA n-3 in the last 6 months; weight loss&gt; 10% in 6 months,&#xD;
             chronic liver disease, previous chronic kidney disease, anorexia, decompensated&#xD;
             diabetes mellitus and dementia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilza AF Peres, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Post-graduation in Nutrition, Institute of Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wilza AF Peres, PhD</last_name>
    <phone>552139386432</phone>
    <email>wilza@nutricao.ufrj.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imanuelly B Gonçalves, MsC</last_name>
    <phone>552134396432</phone>
    <email>imanuely.goncalves@oncoclinicas.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal University of Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941913</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Wilza AF Peres, PhD</last_name>
      <phone>552134386432</phone>
      <email>wilza@nutricao.ufrj.br</email>
    </contact>
    <contact_backup>
      <last_name>B</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Wilza Arantes Ferreira Peres</investigator_full_name>
    <investigator_title>Associate professor, Institute of Nutrition</investigator_title>
  </responsible_party>
  <keyword>fish oils</keyword>
  <keyword>body composition</keyword>
  <keyword>microbiota</keyword>
  <keyword>epigenetics</keyword>
  <keyword>lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

